Dariohealth corp. (DRIO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Revenues

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenues

-

-

-

7,472

-

-

-

6,768

5,919

5,170

4,430

3,783

3,242

2,803

2,273

1,818

1,324

823

566

293

118

51

0

0

0

-

0

0

-

-

-

-

-

Cost of revenues

4,166

4,962

5,481

5,897

6,109

5,629

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of revenues

-

-

-

-

-

-

-

-

-

-

-

-

3,595

3,364

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,774

1,955

2,150

2,274

1,611

1,026

0

-

0

0

-

-

-

-

-

Gross profit

2,818

2,597

1,980

1,575

1,771

1,765

2,111

1,919

1,757

1,311

95

-105

-622

-830

-442

-649

-727

-855

-1,697

-2,151

-2,521

-2,712

-1,611

-1,026

0

-

0

0

-

-

-

-

-

Operating expenses:
Research and development

3,921

3,692

3,779

3,917

3,936

3,676

3,596

3,396

3,570

3,297

3,027

2,889

2,226

2,154

2,151

2,159

2,079

2,565

2,725

2,827

3,719

3,943

4,952

5,261

5,344

4,912

3,658

2,971

2,004

1,501

0

0

0

Sales and marketing

11,272

11,127

12,064

13,015

12,391

10,309

9,049

7,910

7,746

7,707

7,252

7,108

6,045

4,739

3,593

2,477

1,597

1,330

1,083

918

1,029

1,063

1,341

1,852

2,143

2,354

2,091

1,456

792

295

0

0

0

General and administrative

10,081

5,483

4,587

4,348

5,580

5,468

5,345

5,417

3,570

4,726

4,952

4,776

4,490

3,378

2,943

3,670

3,441

2,948

2,911

2,480

3,198

3,640

4,526

5,022

5,246

6,296

5,750

4,856

3,758

2,177

0

0

0

Total operating expenses

25,274

20,302

20,430

21,280

21,907

19,453

17,990

16,723

14,886

15,730

15,231

14,773

12,761

10,271

8,687

8,306

7,117

6,843

6,719

6,225

7,946

8,646

10,405

12,079

0

-

0

0

-

-

-

-

-

Operating loss

-22,456

-17,705

-18,450

-19,705

-20,136

-17,688

-15,879

-14,804

-13,129

-14,419

-15,136

-14,878

-13,383

-11,101

-9,129

-8,955

-7,844

-7,698

-8,416

-8,376

-10,467

-11,358

-12,430

-13,161

-13,154

-13,562

-11,500

-9,285

-6,555

-3,974

0

0

0

Revaluation of warrants

-

-

-

0

-

-1

-2

-3

-28

1,168

1,837

-950

503

-260

-1,122

913

11

-571

573

-1,280

-2,202

-2,194

0

0

0

-

-

-

-

-

-

-

-

Revaluation of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,591

-5,432

-3,763

-1,606

0

0

0

Issuance cost related to warrants to investors and service provider

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Financial expense, net

-

-

-96

-99

-

-116

-208

-194

-148

-156

644

-39

-46

-46

-700

-57

-17

-15

-44

-3,185

-3,266

-3,713

-3,675

-540

-519

-76

-84

-43

-23

-105

0

0

0

Total financial expenses (income), net

204

-31

-96

-99

-124

-115

-206

-191

-120

-1,324

-1,193

911

-549

214

422

-970

-28

556

-617

-1,905

-1,064

-1,519

3,168

3,505

1,466

-369

-3,676

-5,476

-3,787

-1,712

0

0

0

Net loss

-22,252

-17,736

-18,546

-19,804

-20,260

-17,803

-16,085

-14,995

-13,249

-15,743

-16,329

-13,967

-13,932

-10,887

-8,707

-9,925

-7,872

-7,142

-9,033

-10,281

-11,531

-12,877

-9,262

-9,656

-11,688

-13,931

-15,176

-14,761

-10,342

-5,686

0

0

0

Deemed dividend related to warrant exchange agreement

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend

0

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend related to May 2015 exchange agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

Deemed dividend related to Series A Preferred Stock exchange agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

455

0

0

-

0

-

-

-

0

0

-

-

0

-

-

-

-

-

-

Deemed dividend related to extension of July 2015 Series A warrants in July 2016

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

2,977

0

0

-

0

-

-

-

0

-

-

-

-

-

-

Net loss attributable to holders of Common Stock

-26,682

-20,891

-18,546

-19,804

-20,753

-18,296

-16,833

-15,743

-13,504

-15,998

-16,329

-14,232

-14,197

-11,607

-9,427

-10,380

-8,481

-7,296

-11,958

-13,383

0

-

0

0

-

-

0

-

-

-

-

-

-

Net loss per share:
Basic and diluted net loss per share

-1.57

11.11

-0.06

-0.13

-2.92

16.32

-0.17

-0.32

-0.20

3.12

-0.30

-0.43

-0.75

3.74

-0.15

-0.73

-0.77

7.39

-0.90

-1.26

-1.39

-

-

-

-0.70

-

-

-

-

0.83

-0.25

-0.07

-0.05

Weighted average number of Common Stock used in computing basic and diluted net loss per share **)

3,090

-86,024

50,730

42,519

1,839

-53,595

23,533

19,801

14,943

11,845

9,950

9,521

7,195

5,866

5,705

5,587

3,652

2,655

2,079

1,680

1,175

-

-

-

4,254

-

-

-

-

14,474

12,167

11,957

10,899

Basic loss per share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.66

-0.14

-

-

-0.85

-0.29

-0.35

-

-

-

-

Weighted average number of common stock used in computing basic net loss per share (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,610

22,985

-

-

3,994

18,327

14,808,563

-

-

-

-

Diluted loss per share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.66

-0.15

-

-

-0.85

-0.29

-0.35

-

-

-

-

Weighted average number of common stock used in computing diluted net loss per share (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,610

23,202

-

-

3,994

18,327

14,808

-

-

-

-